Aquestive Therapeutics, Inc. (AQST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q4 '17: 66.9M Q1 '18: 73.9M Q2 '18: 76.7M Q3 '18: 62.8M Q4 '18: 67.4M Q1 '19: 56.7M Q2 '19: 53.9M Q3 '19: 53M Q4 '19: 52.6M Q1 '20: 48.7M Q2 '20: 59.3M Q3 '20: 55.1M Q4 '20: 45.8M Q1 '21: 48.2M Q2 '21: 41.9M Q3 '21: 46.9M Q4 '21: 50.8M Q1 '22: 52M Q2 '22: 49.9M Q3 '22: 48.1M Q4 '22: 47.7M Q1 '23: 46.5M Q2 '23: 46.5M Q3 '23: 48.1M Q4 '23: 50.6M Q1 '24: 51.5M Q2 '24: 58.4M Q3 '24: 58.9M Q4 '24: 57.6M Q1 '25: 54.2M Q2 '25: 44.1M Q3 '25: 43.4M Q4 '25: 44.5M Q1 '26: 50.3M Q2 '26: 54.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q4 '19: 32.2M Q1 '20: 28.2M Q2 '20: 40.6M Q3 '20: 38.2M Q4 '20: 32.9M Q1 '21: 36.1M Q2 '21: 28.9M Q3 '21: 32.5M Q4 '22: 28.3M Q1 '23: 26.6M Q2 '23: 25.2M Q3 '23: 26.6M Q4 '23: 29.8M Q1 '24: 31M Q2 '24: 40M Q3 '24: 40.9M Q4 '24: 39.7M Q1 '25: 37.1M Q2 '25: 27M Q3 '25: 26.2M Q4 '25: 26M Q1 '26: 31.9M Q2 '26: 36.3M Q1 '20 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q4 '18: -49M Q1 '19: -67.3M Q2 '19: -53.3M Q3 '19: -55.1M Q4 '19: -52.7M Q1 '20: -53.5M Q2 '20: -34.4M Q3 '20: -37.2M Q4 '20: -42.9M Q1 '21: -37.6M Q2 '21: -44.5M Q3 '21: -38.7M Q4 '21: -34.7M Q1 '22: -35.9M Q2 '22: -42.1M Q3 '22: -43M Q4 '22: -42.1M Q1 '23: -36.9M Q2 '23: -28.4M Q3 '23: -21.9M Q4 '23: -15.1M Q1 '24: -19.5M Q2 '24: -15.2M Q3 '24: -21.1M Q4 '24: -30.8M Q1 '25: -41.2M Q2 '25: -52.6M Q3 '25: -55.8M Q4 '25: -71.1M Q1 '26: -55.9M Q2 '26: -52.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '17: -8.9M Q1 '18: -3.4M Q2 '18: -34M Q3 '18: -57.5M Q4 '18: -61.4M Q1 '19: -80.2M Q2 '19: -64.2M Q3 '19: -67.6M Q4 '19: -66.2M Q1 '20: -68M Q2 '20: -49.9M Q3 '20: -48.1M Q4 '20: -55.8M Q1 '21: -53.9M Q2 '21: -64M Q3 '21: -62M Q4 '21: -70.5M Q1 '22: -69.1M Q2 '22: -73M Q3 '22: -71M Q4 '22: -54.4M Q1 '23: -33.1M Q2 '23: -22.6M Q3 '23: -12.1M Q4 '23: -7.9M Q1 '24: -28.8M Q2 '24: -25.7M Q3 '24: -35.2M Q4 '24: -44.1M Q1 '25: -54.2M Q2 '25: -65M Q3 '25: -69M Q4 '25: -83.8M Q1 '26: -68.9M Q2 '26: -78.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 8M 16M 24M Q4 '19: 20.4M Q1 '20: 20.5M Q2 '20: 18.6M Q3 '20: 17M Q4 '20: 13M Q1 '21: 12.1M Q2 '21: 13M Q3 '21: 14.4M Q4 '22: 19.4M Q1 '23: 19.9M Q2 '23: 21.3M Q3 '23: 21.5M Q4 '23: 20.8M Q1 '24: 20.5M Q2 '24: 18.4M Q3 '24: 18M Q4 '24: 17.9M Q1 '25: 17.1M Q2 '25: 17.2M Q3 '25: 17.2M Q4 '25: 18.6M Q1 '26: 18.4M Q2 '26: 17.8M Q1 '20 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '18: -13M Q1 '19: -31.5M Q2 '19: -49.1M Q3 '19: -52.4M Q4 '19: -60.2M Q1 '20: -56.2M Q2 '20: -49M Q3 '20: -42.5M Q4 '20: -45.5M Q1 '21: -45.9M Q2 '21: -37.7M Q3 '21: -38.4M Q4 '21: -33M Q1 '22: -33.4M Q2 '22: -38.2M Q3 '22: -26.3M Q4 '22: -9.8M Q1 '23: 13.5M Q2 '23: 12.1M Q3 '23: 7M Q4 '23: -6.4M Q1 '24: -25.6M Q2 '24: -24.7M Q3 '24: -34.2M Q4 '24: -35.8M Q1 '25: -48.8M Q2 '25: -49.7M Q3 '25: -50.5M Q4 '25: -52.4M Q1 '26: -43.8M Q2 '26: -45.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '18: -14.8M Q1 '19: -33.4M Q2 '19: -50.6M Q3 '19: -53.5M Q4 '19: -60.9M Q1 '20: -56.6M Q2 '20: -49.4M Q3 '20: -42.9M Q4 '20: -46M Q1 '21: -46.4M Q2 '21: -38.2M Q3 '21: -39M Q4 '21: -33.9M Q1 '22: -34.3M Q2 '22: -39.6M Q3 '22: -27.8M Q4 '22: -10.8M Q1 '23: 12.6M Q2 '23: 11.1M Q3 '23: 6M Q4 '23: -7.4M Q1 '24: -26.6M Q2 '24: -24.9M Q3 '24: -34.4M Q4 '24: -35.9M Q1 '25: -49M Q2 '25: -50M Q3 '25: -50.9M Q4 '25: -53M Q1 '26: -44.3M Q2 '26: -45.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '18: 19.2M Q3 '18: 23.6M Q2 '19: 25M Q3 '19: 25M Q1 '20: 33.6M Q3 '20: 33.6M Q1 '21: 35.6M Q2 '21: 37.1M Q3 '21: 39.2M Q1 '22: 41.5M Q2 '22: 45.5M Q3 '22: 53.4M Q1 '23: 73.8M Q2 '23: 57.4M Q3 '23: 64.7M Q1 '24: 73.6M Q2 '24: 90.9M Q3 '24: 91.1M Q1 '25: 95.5M Q2 '25: 99.3M Q3 '25: 110.6M Q1 '26: 122.6M Q2 '26: 125M Q3 '18 Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '18: -2.83 Q1 '19: -3.69 Q2 '19: -2.61 Q3 '19: -2.71 Q4 '19: -2.63 Q1 '20: -2.53 Q2 '20: -1.78 Q3 '20: -1.53 Q4 '20: -1.66 Q1 '21: -1.58 Q2 '21: -1.84 Q3 '21: -1.72 Q4 '21: -1.84 Q1 '22: -1.75 Q2 '22: -1.78 Q3 '22: -1.64 Q4 '22: -1.13 Q1 '23: -0.70 Q2 '23: -0.44 Q3 '23: -0.24 Q4 '23: -0.15 Q1 '24: -0.43 Q2 '24: -0.36 Q3 '24: -0.46 Q4 '24: -0.52 Q1 '25: -0.59 Q2 '25: -0.70 Q3 '25: -0.71 Q4 '25: -0.79 Q1 '26: -0.62 Q2 '26: -0.66 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.